The critical detail here is that you can't say that a compounded GLP-1 is "basically identical to" the real thing, because that's substantively not true
The study showed significant decreases in HOMA2-B scores, proinsulin/insulin ratios, and proinsulin/C-peptide ratios in both tirzepatide (all doses) and dulaglutide compared to placebo [66]
He encourages his patients to focus on building sustainable habits while on these medications, which they can continue once they discontinue GLP-1s in preparation for pregnancy
Some of the medication will break down, he adds, but enough will make it across to result in health improvements
"The barriers to use and reuse are getting so low that it's a little hard to project." As with many things relating to GLP-1s, consumer behavior is far outpacing research about the effects of their use in different situations
For Canadian patients who choose the research peptide pathway, quality verification becomes critical